Oral Alternatives to Metformin for Type 2 Diabetes

First-Line Oral Alternatives

The American Diabetes Association recommends sulfonylureas, such as glipizide or glimepiride, as the most appropriate first-line oral alternatives for most patients with type 2 diabetes who cannot take metformin, with DPP-4 inhibitors, such as linagliptin, as a safer option when hypoglycemia risk is a concern, in patients with normal renal function, with a moderate strength of evidence 1, 2
The American College of Physicians suggests that glipizide is the safest sulfonylurea in renal impairment because it has no active metabolites and does not accumulate in chronic kidney disease, in patients with renal impairment, with a high strength of evidence 3

The Kidney International journal recommends DPP-4 inhibitors, such as linagliptin, as excellent alternatives when hypoglycemia risk must be minimized, as they have minimal hypoglycemia risk and are weight-neutral, in patients with type 2 diabetes, with a moderate strength of evidence 2, 4
The Annals of Internal Medicine suggests that linagliptin requires no dose adjustment at any level of renal function, making it the most versatile DPP-4 inhibitor, in patients with renal impairment, with a high strength of evidence 4

The Diabetes Care journal recommends pioglitazone as an alternative for insulin resistance, as it improves insulin sensitivity and may be more durable in effectiveness than sulfonylureas, but significant side effects limit its use, in patients with type 2 diabetes, with a moderate strength of evidence 1, 2

The Kidney International journal suggests that if eGFR ≥45 mL/min/1.73 m², the first choice should be glimepiride 1-4 mg daily or glipizide 5-20 mg daily, in patients with normal renal function, with a moderate strength of evidence 2
The Annals of Internal Medicine recommends that if hypoglycemia risk is high, linagliptin 5 mg daily or sitagliptin 100 mg daily should be used, in patients with type 2 diabetes, with a moderate strength of evidence 2, 4

The American College of Cardiology states that metformin is contraindicated in patients with eGFR <30 mL/min/1.73 m², known hepatic disease or liver failure, acute illness causing volume depletion, and alcoholism, due to the risk of metformin-associated lactic acidosis, in patients with type 2 diabetes, with a high strength of evidence 1, 2, 5

The American Diabetes Association recommends checking HbA1c every 3 months until glycemic targets are achieved, then every 6 months if stable, in patients with type 2 diabetes, with a moderate strength of evidence 6
The Kidney International journal suggests assessing fasting blood glucose regularly during titration to determine dose effectiveness, in patients with type 2 diabetes, with a moderate strength of evidence 6